In the dynamic world of healthcare, identifying unmet needs and swiftly addressing them is our motto. In the past year, we have successfully identified and bridged a gap in neonatal nutrition. The result? NeoMega36®! From the outset, we have embraced a data-driven approach to product… Read More »NeoMega36®: Neobiomics’ Journey to Bridging Unmet Needs
Reflecting on the events that transpired within our company over the past year, the initial impression may not reveal significant changes. However, delving deeper into the details unveils a story of remarkable growth and development. At the onset of the year, Carla Martino became an… Read More »Looking back at 2023
On February 24, 2024, we attended the annual Preterm Symposium in Cologne, organised by the Neonatal Unit at the University of Cologne, Germany. This is a long tradition in Cologne, and the Head of the NICU, Dr. Angela Kribs, conducted this symposium for the 20th… Read More »The Annual Symposium in Cologne
Emma Höglund has been appointed as the new Chief Executive Officer (CEO) of Neobiomics, starting her position on April 15, 2024. Stefan Johansson, co-founder and current CEO, will take on a new position as Chief Medical Officer (CMO). Emma Höglund brings more than 15 years… Read More »Emma Höglund has been appointed as the new CEO of Neobiomics
NeoMega36® is the most recent product launched by Neobiomics. It is a Food for Special Medical Purposes, with a nutritional content tailored for preterm infants. It contains Arachidonic acid (ARA) and Docosahexaenoic acid (DHA) which are omega fatty acids, essential for infants. With the product’s… Read More »NeoMega36® launch